menu
    • menu

    Company profile for PulseSight Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PulseSight Therapeutics is actively progressing a promising pipeline of novel non-viral minimally-invasive gene therapies. The company's focus is on addressing the unmet needs for treating severe retinal diseases that can lead to blindness. PulseSight Therapeutics specifically targets conditions such as age-related macular degeneration (AMD), including wet AMD and late-stage dry AMD or Geographic atrophy (GA). The development ...
    PulseSight Therapeutics is actively progressing a promising pipeline of novel non-viral minimally-invasive gene therapies. The company's focus is on addressing the unmet needs for treating severe retinal diseases that can lead to blindness. PulseSight Therapeutics specifically targets conditions such as age-related macular degeneration (AMD), including wet AMD and late-stage dry AMD or Geographic atrophy (GA). The development of these gene therapies aims to provide innovative and effective solutions for severe retinal diseases that currently lack satisfactory treatments.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PulseSight TherapeuticsFrance Flag
    Country
    Country
    France
    Address
    Address
    11 Rue Watt Bat B, 75013, Paris
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pulsesight.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pulsesight-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pulsesight Therapeutics Completes Phase I Trial For PST-611
    Pulsesight Therapeutics Completes Phase I Trial For PST-611

    23 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-23/last-patient-last-visit-completed-in-phase-i-clinical-trial-of-pulsesight-therapeutics-pst-611-treatment-for-dry-amdgeographic-atrophy-ga

    PHARMIWEB
    23 Apr 2026
    Share Share
    PulseSight Wraps Ph I PST-611 for Dry AMD/Geographic Atrophy (GA)
    PulseSight Wraps Ph I PST-611 for Dry AMD/Geographic Atrophy (GA)

    22 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-22/dosing-completed-in-the-phase-i-clinical-trial-of-pulsesight-therapeutics-pst-611-treatment-for-dry-amdgeographic-atrophy-ga

    PHARMIWEB
    22 Jan 2026
    Share Share
    PulseSight Study Shows Iron Dysregulation Drives Dry AMD/GA
    PulseSight Study Shows Iron Dysregulation Drives Dry AMD/GA

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3165902/0/en/Peer-Reviewed-Publication-Provides-Evidence-for-Iron-Dysregulation-as-a-Driver-of-Dry-AMD-GA-and-the-Potential-of-Transferrin-to-Restore-Iron-Balance-Reinforcing-PulseSight-s-Thera.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share
    Pulse Sight Therapeutics Doses First Patient in Phase I Trial
    Pulse Sight Therapeutics Doses First Patient in Phase I Trial

    07 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/07/3110761/0/en/First-patient-dosed-in-the-Phase-I-clinical-trial-of-PulseSight-Therapeutics-PST-611-treatment-for-dry-AMD-Geographic-Atrophy.html

    GLOBENEWSWIRE
    07 Jul 2025
    Share Share
    PulseSight Secures Series A Funding For PST-611 In Dry AMD
    PulseSight Secures Series A Funding For PST-611 In Dry AMD

    13 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/13/3025626/0/en/PulseSight-Therapeutics-Announces-First-Close-of-its-Series-A-Financing-to-Fund-Clinical-Development-of-PST-611-in-dry-AMD.html

    GLOBENEWSWIRE
    13 Feb 2025
    Share Share
    PulseSight Initiates PST-611 Plan for Dry AMD/Geographic Atrophy
    PulseSight Initiates PST-611 Plan for Dry AMD/Geographic Atrophy

    14 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/14/3009029/0/en/PulseSight-Therapeutics-announces-the-initiation-of-the-clinical-plan-of-PST-611-Transferrin-Vectorized-Therapy-for-dry-AMD-Geographic-Atrophy.html

    GLOBENEWSWIRE
    14 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search